Emmaus Life Sciences Inc (PK:EMMA)
Business Focus: Biotechnology & Medical Research
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 |
| Tel: | N/A |
| Website: | https://www.emmausmedical.com |
| IR: | See website |
| Key People | ||
| Willis C. Lee Chairman of the Board, Co-President, Chief Operating Officer, Executive Director | George Sekulich Co-President, Senior Vice President - Global Commercialization, Chief Information Officer, Director | Yasushi Nagasaki Chief Financial Officer | Charles Stark Senior Vice President - Medical Affairs, Clinical, Regulatory |
| Business Overview |
| Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing, and sale of treatments and therapies, primarily for rare and orphan diseases. The Company's lead product, Endari (prescription-grade L-glutamine oral powder), helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients aged five years and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainos's IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. It has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells. |
| Financial Overview |
| For the nine months ended 30 September 2023, Emmaus Life Sciences Inc revenues increased 81% to $22.5M. Net loss decreased 54% to $4.9M. Revenues reflect Endari segment increase of 82% to $21.9M, Other segment increase of 56% to $605K. Lower net loss reflects Foreign exchange loss decrease of 37% to $3.2M (expense), Research and development decrease of 14% to $1M (expense). |
| Employees: | 55 as of Dec 31, 2022 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $36.56M as of Sep 30, 2023 |
| Annual revenue (TTM): | $28.46M as of Sep 30, 2023 |
| EBITDA (TTM): | $0.81M as of Sep 30, 2023 |
| Net annual income (TTM): | -$4.74M as of Sep 30, 2023 |
| Free cash flow (TTM): | -$0.88M as of Sep 30, 2023 |
| Net Debt Last Fiscal Year: | $30.93M as of Sep 30, 2023 |
| Shares outstanding: | 53,637,554 as of Nov 10, 2023 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.